[Posttreatment hypothyroidism in diffuse toxic goiter. A complication or evolution?].
Hypothyroidism posttreatment of diffuse toxic goiter (DTG) might depend on both treatment of inherent disease factors. 147 patients afflicted with DTG, with at least 3 years under treatment, were studied to identify these factors. Clinical evaluation was performed and TSH and T4T were measured (RIA). 49% had hypothyroidism, 17% of this percentage having been diagnosed during the study. We found these hypothyroidism protector factors: familiar background of thyroid disease, gap between doses of 131 1 greater than of 8 months and as favoring factor: surgical treatment.
Navarro Despaigne
D
D
Instituto Superior de Ciencias Médicas, Hospital Docente Clínico Quirúrgico 12 de Octubre, Ciudad de La Habana, Cuba.
Ripoll Ripoll
F
F
D003131:Combined Modality Therapy; D006111:Graves Disease / Q000097:blood / Q000150:complications* / Q000628:therapy; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000209:etiology*; D013960:Thyroid Function Tests; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D013997:Time Factors
D013972:Thyrotropin; D013974:Thyroxine
Hipotiroidismo post tratamiento del bocio tóxico difuso. Complicación o evolución?